Navigation Links
Met-Pro Corporation Acquires Patented Biological Technology

HARLEYSVILLE, Pa., Oct. 12 /PRNewswire-FirstCall/ -- Raymond J. De Hont, Chairman and Chief Executive Officer of Met-Pro Corporation (NYSE: MPR), announced today that the Company has acquired substantially all of the assets including the patents and technology of Bio-Reaction Industries LLC ("BRI"), a pioneer in environmentally friendly air pollution control systems utilizing state-of-the-art biological technology to eliminate volatile organic compounds (VOCs), hazardous air pollutants (HAPs), and odors.

"The acquisition of these assets significantly enhances Met-Pro's competitive position in both the municipal and industrial global markets by providing not only state-of-the-art biological technologies, but also a broad global reference base of satisfied customers," stated De Hont. "BRI's patented biological technology, which is a perfect complement to our Met-Pro Environmental Air Solutions' thermal oxidizer and chemical scrubber technologies, strengthens our "Total Air Solutions" value proposition, allowing us to better address the increasingly more stringent environmental regulations and the global focus on greenhouse gas reduction. We believe our extensive relationships within the municipal market will enable us to quickly grow BRI's municipal market share, while BRI's relationships within a diverse base of industrial markets provides opportunities to introduce Met-Pro's broad range of solutions to new markets."

BRI's bio-oxidation systems are the new standard in air pollution control technology, utilizing naturally existing microbes to biologically break down HAPs and VOCs. BRI offers a modular, reliable bio-oxidation solution that achieves the highest removal efficiency of VOCs for any air phase biological treatment system in the world. BRI's innovative vapor-phase bio-technologies provide a cost effective way to comply with regulatory requirements, treating high volume, low concentration air streams and delivering dramatic energy savings for a wide range of applications, including municipalities, paints and coatings, wood products, building materials, and the chemical processing industry. BRI's patented Bio-airSPHERES enhance microbial activity and air contaminant digestion, effectively reducing carbon footprints and significantly cutting operating costs when compared with other less efficient technologies.

Terms of the transaction were not disclosed. It is expected that the acquisition will have no impact upon current year earnings but will be accretive to earnings in the Company's fiscal year ending January 31, 2012.

About Bio-Reaction Industries LLCBio-Reaction Industries LLC, Tualatin, Oregon, designs and manufactures biological air pollution control systems that utilize microbes to digest industrial and municipal pollutants and eliminate odors.

BRI is a global leader in the emerging, energy efficient biofiltration industry with strategic partners established and operating in both Europe and Asia. Numerous research and development programs are in place as BRI continues to develop the next generation of biofiltration air control technologies.  

BRI serves the wood products, paint and coating, chemical processing, municipal utility, food and beverage and automotive industries. Customers include Louisiana Pacific, Weyerhaeuser, Sherwin Williams, Bangor Naval Station, and municipalities such as Wilsonville, Oregon and Falmouth, Massachusetts. For more information, visit:

About Met-ProMet-Pro Corporation, with headquarters at 160 Cassell Road, Harleysville, Pennsylvania, is a leading niche-oriented global provider of product recovery, pollution control and fluid handling solutions. The Company's diverse and synergistic solutions and products address the world's growing need to meet more stringent emission regulations, reduce energy consumption and employ green technology. Through its global sales organization, internationally recognized brands, and operations in the United States, Canada, Europe and The People's Republic of China, Met-Pro's solutions, products and systems are sold to a well-diversified cross-section of customers and markets around the world. For more information, please visit

The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Certain information included in this news release, and other materials filed or to be filed with the Securities and Exchange Commission (as well as information included in oral or other written statements made or to be made by the Company), contain statements that are forward-looking. Such statements may relate to plans for future expansion, business development activities, capital spending, financing, the effects of regulation and competition, or anticipated sales or earnings results. Such information involves risks and uncertainties that could significantly affect results in the future and, accordingly, such results may differ from those expressed in any forward-looking statements made by or on behalf of the Company. These risks and uncertainties include, but are not limited to, those relating to, the cancellation or delay of purchase orders and shipments, product development activities, goodwill impairment, computer systems implementation, dependence on existing management, the continuation of effective cost and quality control measures, retention of customers, global economic and market conditions, and changes in federal or state laws.

Met-Pro common shares are traded on the New York Stock Exchange, symbol MPR.

To obtain an Annual Report or additional information on the Company, please call 215-723-6751 and ask for the Investor Relations Department, or visit the Company's website at Investor Contact:Gary J. Morgan

Joseph Hassett, SVPSenior Vice President of Finance, CFO

Gregory FCA Communications215-723-6751


SOURCE Met-Pro Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Met-Pro Corporation Declares Quarterly Dividend
2. Verenium Corporation to Present at Canaccord Adams 28th Annual Global Growth Conference
3. Pharmos Corporation Reports 2008 Second Quarter Results
4. China Bionanometer Industries Corporation Promotes New Product Beauty Look in China
5. Genaera Corporation Announces Second Quarter Financial Results
6. MannKind Corporation Reports Second Quarter Financial Results
7. [video] David Brown, President and CEO of LifeVantage Corporation, Discusses Record Page Views on WallSt.nets 3-Minute Press Show
8. Emerging Growth Equities, Ltd. Initiates Coverage of CombiMatrix Corporation with a BUY Rating and an $18.00 Price Target
9. CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results
10. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Generex Biotechnology Corporation
11. Mymetics Corporation Important Shareholders Information Conference Call
Post Your Comments:
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, ... microbial test has received AOAC Research Institute approval 061601. , “This is another ... year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... announced the launch of the Supplyframe Design Lab . Located in Pasadena, ... explore the future of how hardware projects are designed, built and brought to ...
(Date:6/23/2016)... BEACH, Calif. , June 23, 2016  Blueprint ... new biological discoveries to the medical community, has closed ... co-founder Matthew Nunez . "We have ... us with the capital we need to meet our ... will essentially provide us the runway to complete validation ...
Breaking Biology Technology:
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted to ... of 2015 The gross margin was 49% (27) ... operating margin was 40% (-13) Earnings per share rose ... was SEK 249.9 M (21.2) , Outlook   ... The operating margin for 2016 is estimated to exceed ...
(Date:4/15/2016)... CHICAGO , April 15, 2016  A ... companies make more accurate underwriting decisions in a ... offering timely, competitively priced and high-value life insurance ... health screenings. With Force Diagnostics, rapid ... and lifestyle data readings (blood pressure, weight, pulse, ...
(Date:3/31/2016)... Florida , March 31, 2016 ... ) ("LegacyXChange" or the "Company") LegacyXChange ... potential users of its soon to be launched online ... ( ) will also provide potential ... use of DNA technology to an industry that is ...
Breaking Biology News(10 mins):